Company Active LTD

Company profile

CC Biotech LTD.

403 Forbidden

CC Biotech LTD. is a UK company with status active founded in 2018 based in East of England.

CRN
11541952
Founded
2018
Age
7

Overview

Legal name
CC BIOTECH LTD.
Region
East of England
Registered address
THE CAMBRIDGE PARTNERSHIP, DOROTHY HODGKIN BLDG BABRAHAM RESEARCH CAMPUS
BABRAHAM
CAMBRIDGE
ENGLAND
CB22 3FH
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

7 events
31 Mar
2027

Accounts due

Accounts Due

Next accounts due date

11 Sep
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

28 Aug
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Jun
2025

Accounts filed

Accounts

Last accounts made up date

29 Aug
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQzMzg0NDgyMmFkaXF6a2N4

Published 29 Aug 2024 17:08

16 Aug
2024

Accounts With Accounts Type Total Exemption Full

Accounts Awaiting analysis

AA | Transaction MzQzMjUwODk2MmFkaXF6a2N4

Published 16 Aug 2024 14:30

29 Aug
2018

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2020
Funded years
2020, 2023, 2025
Age at first award
1 years

Projects

2025 Collaborative R&D Lead participant

Novel Biomanufacturing Strategies for Scalable Production of Non-Donor-Derived FMT Products

1 Jul 2025 to 31 Mar 2028

Awarded
£175,713
Total cost £251,019

**The Bacterial Microbiome: Key to our Health** Bacteria from a critical element of who we are: indeed, we carry approximately the same amount of bacterial cells around with us as the human cells which make up our body. These bacteria that grow and thrive on all of our internal and external surfaces are known as our microbiome. We play host to several dif...

2023 Collaborative R&D Lead participant

Treatment of Recurrent Bacterial Vaginosis Using Engineered Probiotic Bacteria

1 Jan 2023 to 31 Jan 2025

Awarded
£340,973
Total cost £487,104

**Public description** This project aims to develop new therapies for the prevention of recurrent bacterial vaginosis (BV). Around 30% of women suffer from BV, making it the most common vaginal infection of women of childbearing age. BV is caused by the overgrowth of unwanted bacteria within the vagina. The main problematic bacterium which causes BV is ca...

2020 Feasibility Studies Lead participant

Continuity Grant for Project 105472/37800

1 Jun 2020 to 30 Nov 2020

Awarded
£28,900
Total cost £28,900

no public description

2020 Study Lead participant

Development of clinically translatable therapies for the treatment and prevention of bacterial vaginosis

1 Feb 2020 to 31 Oct 2021

Awarded
£122,378
Total cost £174,826

This research aims to develop new therapies for the treatment of recurrent bacterial vaginosis (BV). BV is the most common vaginal infection experienced by women of childbearing age, with up to 30% of woman of this group affected by the condition. BV is caused by the overgrowth of unwanted bacteria within the vagina. The main problematic bacterium which c...

Product types

Collaborative R&D Feasibility Studies Study